Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longitudinal Tau PET Imaging with [18F]RO6958948 in Alzheimer's Disease
NCT02792179Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]RO-948 in Alzheimer's disease (AD), sponsored by Roche. Primary endpoints: Regional Standardized Uptake Value at Day 1, Regional Standardized Uptake Value Ratio at Day 1 and 2 more. Started Jul 2016; status: completed.
02
Drugs
[18F]RO-948
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02792179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792179.